GLSI
Greenwich LifeSciences, Inc.NASDAQHealthcare$22.82-0.61%ClosedMarket Cap: $316.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
137.54
P/S
0.00
EV/EBITDA
-15.44
DCF Value
$0.23
FCF Yield
-2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1042.8%
ROA
-511.6%
ROIC
-896.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $0.00 | NaN% | $-4.2M | $-4.2M | $-0.30 | — |
| Q2 2025 | $0.00 | -Infinity% | $-4.0M | $-4.0M | $-0.30 | — |
| Q1 2025 | $0.00 | -Infinity% | $-3.3M | $-3.3M | $-0.25 | — |
| Q4 2024 | $0.00 | -Infinity% | $-8.1M | $-8.0M | $-0.61 | — |
| FY 2024 | $0.00 | -Infinity% | $-16.0M | $-15.8M | $-1.21 | — |
| Q3 2024 | $0.00 | -Infinity% | $-2.7M | $-2.7M | $-0.20 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.7M | $-2.6M | $-0.20 | — |
| Q1 2024 | $0.00 | -Infinity% | $-2.5M | $-2.5M | $-0.19 | — |
| Q4 2023 | $0.00 | -Infinity% | $-2.8M | $-2.7M | $-0.21 | — |
| FY 2023 | $0.00 | -Infinity% | $-9.3M | $-8.9M | $-0.69 | — |
| Q3 2023 | $0.00 | -Infinity% | $-2.5M | $-2.4M | $-0.19 | — |
| Q2 2023 | $0.00 | -Infinity% | $-1.7M | $-1.6M | $-0.13 | — |